[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cinnagen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100613144",false,"NCT07262762","Spartina® (Tirzepatide) Effectiveness and Safety Evaluation","A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight","Inclusion Criteria:\n\n1. Male or female ≥18 years of age\n2. Willingness for signing and having signed the informed consent form\n3. BMI ≥30 kg\u002Fm² or ≥27 kg\u002Fm² with ≥1 weight-related comorbidity\n\nExclusion Criteria:\n\n1. Prior use of any GLP-1 agonist in the last 6 months\n2. Type 1 diabetes mellitus\n3. Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data\n4. Pregnancy or breast-feeding\n5. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)","ALL","18 Years",{"count":18,"type":19},175,"ESTIMATED","OBSERVATIONAL","The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered:\n\n1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight?\n2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight?\n\nIn this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)",[23],"Obesity & Overweight",[25,26,27],"obesity","overweight","tirzepatide","RECRUITING","2025-12-08",{"date":31,"type":32},"2025-12-16","ACTUAL",{"date":34,"type":32},"2025-11-11",{"date":36,"type":19},"2026-04",{"name":38,"class":39},"Cinnagen","INDUSTRY",14,""]